Aurinia Pharmaceuticals Inc (AUPH) News
Filter AUPH News Items
AUPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AUPH News Highlights
- AUPH's 30 day story count now stands at 9.
- Over the past 22 days, AUPH's stories per day has been in a clear downtrend, falling by about 0.26 per 2 days.
- The most mentioned tickers in articles about AUPH are ROAD, ROSE and SUN.
Latest AUPH News From Around the Web
Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Aurinia Announces PTAB Has Terminated Inter Partes ReviewVICTORIA, British Columbia, January 25, 2023--Aurinia Announces PTAB Has Terminated Inter Partes Review |
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark OfficeVICTORIA, British Columbia, January 24, 2023--AURINIA PHARMACEUTICALS ANNOUNCES ALLOWANCE OF A NEW AND REFINED METHOD OF USE PATENT FOR LUPKYNIS® IN THE TREATMENT OF LUPUS NEPHRITIS FROM THE USPTO |
Investors ignore increasing losses at Aurinia Pharmaceuticals (NASDAQ:AUPH) as stock jumps 21% this past weekWhen we invest, we're generally looking for stocks that outperform the market average. And while active stock picking... |
Why Shares of Aurinia Pharmaceuticals Soared This WeekShares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were up by 79.6% this week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company, which specializes in treating autoimmune disorders, closed last Friday at $4.32, then rose to as high as $7.80 in the early afternoon this Friday. Aurinia reported full-year revenue of $134 million, up 112% over 2021. |
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue ResultsVICTORIA, British Columbia, January 06, 2023--AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2022 NET REVENUE RESULTS |
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare ConferenceVICTORIA, British Columbia, January 04, 2023--AURINIA PHARMACEUTICALS TO PRESENT AT UPCOMING 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE |
Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VICTORIA, British Columbia, January 03, 2023--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun PharmaceuticalsVICTORIA, British Columbia, January 03, 2023--AURINIA ANNOUNCES LUPKYNIS® (voclosporin) PATENT CHALLENGE SETTLEMENT REACHED WITH SUN PHARMACEUTICALS |
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus NephritisVICTORIA, British Columbia, November 30, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus |